506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma
• •* Tumor cells should exhibit phenotypic characteristics of these diseases
• •No CNS involvement requiring intrathecal or craniospinal radiotherapy
• •Must not be eligible for Intergroup, Cooperative Group, or local research studies of higher priority
• •PATIENT CHARACTERISTICS:
• •Age:
• •16 and over
• •Performance status:
• •ECOG 0-3 OR
• •Karnofsky 40-100%
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •Not specified
• •Hepatic:
• •Bilirubin no greater than 2.0 mg/dL
• •Renal:
• •Creatinine no greater than 1.5 mg/dL OR
• •Creatinine clearance at least 50 mL/min
• •Other:
• •No neuropathy grade 2 or higher
• •No history of significant neurological toxicity (grade 2 or greater) associated with prior chemotherapy or radiotherapy
• •No active seizure disorder
• •No active infection
• •No other active concurrent malignancy except curatively treated basal cell carcinoma or carcinoma in situ of the cervix
• •Not pregnant or nursing
• •Fertile patients must use effective contraception
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Prior bone marrow transplantation allowed
• •No concurrent allogeneic bone marrow transplantation
• •Chemotherapy:
• •At least 3 weeks since prior chemotherapy (6 weeks for nitrosourea or mitomycin) and recovered
• •No prior 506U78
• •Endocrine therapy:
• •No concurrent systemic steroid therapy
• •Radiotherapy:
• •See Disease Characteristics
• •Prior radiotherapy allowed
• •Surgery:
• •Not specified
• •Other:
• •No other concurrent investigational therapy
• •No concurrent treatment for seizures